Bringing to market CGRP blockers, or antagonists - the most advanced of the new drugs in development for migraines - has proved challenging. Several investigational compounds have been shown to be toxic to the liver, a challenge that highlights the difficulty in developing drugs for conditions that affect the brain.
事实证明,面向市场推出CGRP阻滞药物或者拮抗物──最先进的偏头痛治疗新药──难度很大。好几种正在研制中的药物都被发现对肝脏有毒害作用,这项挑战突显了针对可影响大脑的病症开发药物的难度有多大。
CGRP antagonists don't appear to work as well as triptans, but the blockers have an advantage in they don't appear to cause cardiovascular complications, says Stephen Silberstein, a neurology professor and director of Thomas Jefferson University's Headache Center in Philadelphia.
费城托马斯•杰斐逊大学头痛病研究中心(Thomas Jefferson University's Headache Center)的神经病学教授兼主任史蒂芬•西尔伯斯坦(Stephen Silberstein)说,CGRP拮抗药物的疗效似乎不如曲坦类药物,但是阻滞类药物的优点是它们似乎不会引起心血管并发症。
'You trade one kind of risk for another,' says Dr. Silberstein, who has served as an investigator on several companies' clinical trials.
“你是以一种风险来替代了另一种风险,”西尔伯斯坦医生说。他担任了好几家公司产品临床试验的调研员。
【难治的偏头痛让科学家头痛】相关文章:
最新
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15
2020-09-15